IL125104A - תכשירי רוקחות למניעה ולטיפול בסיבוכי סכרת המכילם חומצת 4[a-הידרוקסי-2- מתיל-5- (-1 אימידאזוליל) בנזיל]-5,3- דימתיל בנזואית, תרכובת בעלת פעילות אופטית הימנה או מלח הימנה - Google Patents

תכשירי רוקחות למניעה ולטיפול בסיבוכי סכרת המכילם חומצת 4[a-הידרוקסי-2- מתיל-5- (-1 אימידאזוליל) בנזיל]-5,3- דימתיל בנזואית, תרכובת בעלת פעילות אופטית הימנה או מלח הימנה

Info

Publication number
IL125104A
IL125104A IL12510496A IL12510496A IL125104A IL 125104 A IL125104 A IL 125104A IL 12510496 A IL12510496 A IL 12510496A IL 12510496 A IL12510496 A IL 12510496A IL 125104 A IL125104 A IL 125104A
Authority
IL
Israel
Prior art keywords
prophylaxis
treatment
diabetic
hydroxy
diabetic complications
Prior art date
Application number
IL12510496A
Other languages
English (en)
Other versions
IL125104A0 (en
Original Assignee
Welfine Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Welfine Corp filed Critical Welfine Corp
Publication of IL125104A0 publication Critical patent/IL125104A0/xx
Publication of IL125104A publication Critical patent/IL125104A/he

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Dental Tools And Instruments Or Auxiliary Dental Instruments (AREA)
IL12510496A 1995-12-27 1996-12-24 תכשירי רוקחות למניעה ולטיפול בסיבוכי סכרת המכילם חומצת 4[a-הידרוקסי-2- מתיל-5- (-1 אימידאזוליל) בנזיל]-5,3- דימתיל בנזואית, תרכובת בעלת פעילות אופטית הימנה או מלח הימנה IL125104A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP34016195 1995-12-27
PCT/JP1996/003776 WO1997024333A1 (en) 1995-12-27 1996-12-24 Preventives/remedies for complications of diabetes

Publications (2)

Publication Number Publication Date
IL125104A0 IL125104A0 (en) 1999-01-26
IL125104A true IL125104A (he) 2002-12-01

Family

ID=18334321

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12510496A IL125104A (he) 1995-12-27 1996-12-24 תכשירי רוקחות למניעה ולטיפול בסיבוכי סכרת המכילם חומצת 4[a-הידרוקסי-2- מתיל-5- (-1 אימידאזוליל) בנזיל]-5,3- דימתיל בנזואית, תרכובת בעלת פעילות אופטית הימנה או מלח הימנה

Country Status (22)

Country Link
US (8) US6060496A (he)
EP (2) EP1394151A1 (he)
JP (1) JP3448869B2 (he)
KR (2) KR100471351B1 (he)
CN (2) CN1159009C (he)
AT (1) ATE252563T1 (he)
AU (1) AU716332B2 (he)
BG (1) BG63803B1 (he)
BR (1) BR9612316A (he)
CA (1) CA2241856C (he)
CZ (1) CZ294485B6 (he)
DE (1) DE69630465T2 (he)
EE (1) EE03524B1 (he)
ES (1) ES2210399T3 (he)
HU (1) HUP0000422A3 (he)
IL (1) IL125104A (he)
IS (1) IS4784A (he)
MX (1) MX9805317A (he)
NO (1) NO316494B1 (he)
NZ (1) NZ324454A (he)
RU (1) RU2173148C2 (he)
WO (1) WO1997024333A1 (he)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL125104A (he) * 1995-12-27 2002-12-01 Welfine Corp תכשירי רוקחות למניעה ולטיפול בסיבוכי סכרת המכילם חומצת 4[a-הידרוקסי-2- מתיל-5- (-1 אימידאזוליל) בנזיל]-5,3- דימתיל בנזואית, תרכובת בעלת פעילות אופטית הימנה או מלח הימנה
CN1160072C (zh) * 1999-05-25 2004-08-04 三菱制药株式会社 Mag表达促进剂
US6482844B1 (en) * 2000-04-07 2002-11-19 Neurogen Corporation 1-benzylimidazole derivatives
EP1352569A1 (en) * 2000-11-24 2003-10-15 Toyo Shinyaku Co., Ltd. Foods containing young wheat leaf powder
DE10229180A1 (de) 2002-06-28 2004-01-29 Aventis Pharma Deutschland Gmbh Verwendung von Vasopeptidase-Inhibitoren bei der Behandlung von metabolischen Erkrankungen, Nephropathie und mit AGE assoziierten Erkrankungen
AU2003270049A1 (en) * 2002-08-29 2004-03-19 University Of Florida Research Foundation Incorporated Cox-2 mediated altered prostaglandin balance in diabetes complications
GB0314945D0 (en) * 2003-06-26 2003-07-30 Black & Decker Inc Vacuum cleaner
TWI338583B (en) * 2004-05-20 2011-03-11 Otsuka Pharma Co Ltd Solid pharmaceutical formulation
US20110015158A1 (en) 2007-12-11 2011-01-20 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
RU2741715C1 (ru) * 2020-03-20 2021-01-28 Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский государственный медицинский университет имени академика Е.А. Вагнера" Министерства здравоохранения Российской Федерации Способ прогнозирования формирования микрососудистых осложнений сахарного диабета 2 типа

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK531479A (da) * 1979-01-19 1980-07-20 Pfizer Fremgangsmaade til fremstilling af imidazolderivater og salte deraf
JPS61277670A (ja) * 1985-06-03 1986-12-08 Yoshitomi Pharmaceut Ind Ltd イミダゾ−ル誘導体
US4661603A (en) * 1982-03-03 1987-04-28 Yoshitomi Pharmaceutical Industries, Ltd. Imidazole derivatives
JPS6147477A (ja) * 1984-08-14 1986-03-07 Kowa Co 新規１，４−ジヒドロピリジン−３，５−ジカルボン酸エステル誘導体
JPS63119425A (ja) * 1986-11-07 1988-05-24 Yoshitomi Pharmaceut Ind Ltd 免疫機能改善薬
GB2205240B (en) * 1987-06-03 1991-01-09 Erba Carlo Spa N-imidazolyl derivatives of bicyclic compounds useful in medicine
JP2814513B2 (ja) * 1988-02-03 1998-10-22 吉富製薬株式会社 溶出性の改良された製剤組成物
WO1989006959A1 (fr) * 1988-02-03 1989-08-10 Yoshitomi Pharmaceutical Industries, Ltd. Preparation pharmaceutique a liberation amelioree
AU5279390A (en) 1989-03-31 1990-11-05 Kyoto Pharmaceutical Industries, Ltd. New imidazole derivatives, production thereof, and uses thereof as medicines
JPH037281A (ja) * 1989-03-31 1991-01-14 Kyoto Yakuhin Kogyo Kk 新規イミダゾール誘導体およびその医薬用途
US5401851A (en) * 1992-06-03 1995-03-28 Eli Lilly And Company Angiotensin II antagonists
IL125104A (he) * 1995-12-27 2002-12-01 Welfine Corp תכשירי רוקחות למניעה ולטיפול בסיבוכי סכרת המכילם חומצת 4[a-הידרוקסי-2- מתיל-5- (-1 אימידאזוליל) בנזיל]-5,3- דימתיל בנזואית, תרכובת בעלת פעילות אופטית הימנה או מלח הימנה

Also Published As

Publication number Publication date
EP0881218A4 (en) 1999-01-27
BG63803B1 (bg) 2003-01-31
RU2173148C2 (ru) 2001-09-10
JP3448869B2 (ja) 2003-09-22
EP0881218A1 (en) 1998-12-02
US6060496A (en) 2000-05-09
KR100471351B1 (ko) 2005-03-14
ES2210399T3 (es) 2004-07-01
US20050239856A1 (en) 2005-10-27
US6258834B1 (en) 2001-07-10
CN1092645C (zh) 2002-10-16
US20020169194A1 (en) 2002-11-14
NO982988D0 (no) 1998-06-26
KR19990064262A (ko) 1999-07-26
BR9612316A (pt) 1999-07-13
WO1997024333A1 (en) 1997-07-10
CA2241856A1 (en) 1997-07-10
EE03524B1 (et) 2001-10-15
AU716332B2 (en) 2000-02-24
IL125104A0 (en) 1999-01-26
US20010036957A1 (en) 2001-11-01
EP0881218B1 (en) 2003-10-22
US20030130332A1 (en) 2003-07-10
ATE252563T1 (de) 2003-11-15
KR20040045002A (ko) 2004-05-31
EE9800208A (et) 1998-12-15
CN1159009C (zh) 2004-07-28
HUP0000422A3 (en) 2001-06-28
HK1015777A1 (en) 1999-10-22
CZ294485B6 (cs) 2005-01-12
AU1173597A (en) 1997-07-28
DE69630465D1 (de) 2003-11-27
NZ324454A (en) 2000-09-29
NO982988L (no) 1998-08-26
KR100443891B1 (ko) 2004-10-14
NO316494B1 (no) 2004-02-02
BG102633A (en) 1999-09-30
US20040171663A1 (en) 2004-09-02
HUP0000422A2 (hu) 2001-04-28
DE69630465T2 (de) 2004-07-22
CN1324618A (zh) 2001-12-05
IS4784A (is) 1998-06-26
MX9805317A (es) 1998-10-31
CZ9802012A3 (cs) 1998-12-16
CA2241856C (en) 2006-10-17
US20060148875A1 (en) 2006-07-06
EP1394151A1 (en) 2004-03-03
CN1209122A (zh) 1999-02-24

Similar Documents

Publication Publication Date Title
EP2616066B1 (en) Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl]methanol for treating retinal diseases
US6060496A (en) Prophylaxis and treatment of diabetic complications with 4-[α-hydroxy-2-methyl-5-(1-imidazolyl) benzyl]-3,5-dimethylbenzoic acid
EP2611415B1 (en) Adenosine a1 agonists for the treatment of glaucoma and ocular hypertension
JPWO1997024333A1 (ja) 糖尿病性合併症の予防・治療剤
EP1243261B1 (en) Use of a hydantoin derivative in a pharmaceutical composition against hypoalbuminaemia
US6197796B1 (en) Anticancer composition comprising a diaminotrifluoromethylpyridine derivative
HK1015777B (en) Preventives/remedies for complications of diabetes
CA2264101A1 (en) Preventives/remedies for muscle tissue degenerations
JP2003221334A (ja) 糖尿病性合併症の予防・治療剤
EP3730143A1 (en) Omidenepag combination
HK40029828A (en) Omidenepag combination
WO1995033456A2 (en) Reducing intraocular pressure using aryloxy- and aryl-acetic acids
HK1185539B (en) Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl]methanol for treating retinal diseases

Legal Events

Date Code Title Description
FF Patent granted
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees